

The Risk Factors of Low Anterior Resection Syndrome After Colorectal Cancer Surgery Compared with the Last Decade Studies

HyokJu Ri

the Second Affiliation Hospital of Dalian Medical University

ZhaoHui Xu

the Second Affiliation Hospital of Dalian Medical University

GunHyok Kim

the Second Affiliation Hospital of Dalian Medical University

YanYing Ren

the Second Affiliation Hospital of Dalian Medical University

Hui Qu

the Second Affiliation Hospital of Dalian Medical University

ZeZhong Gong

the Second Affiliation Hospital of Dalian Medical University

BOUREIMA HAMIDOU AMADOU

the Second Affiliation Hospital of Dalian Medical University

Xin Chen (✉ chenxincjz@gmail.com)

the Second Affiliation Hospital of Dalian Medical University

Research Article

Keywords: low anterior resection syndrome, colorectal cancer, total mesorectal excision

Posted Date: March 11th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1433776/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Purpose

This study aims to identify the independent risk factors compared with the last decade studies in the low anterior resection syndrome (LARS) after surgery for colorectal cancer (CRC).

Method

This was a cross-sectional, single-institution study in the Second Affiliation Hospital of Dalian Medical University, China. Patients underwent sphincter-preserving low anterior resection with total or partial mesorectal resection (with or without protective ileostomy) and completed a self-filled questionnaire over the phone to assess postoperative bowel dysfunction from January 2017 to December 2019. The predictors of LAR were evaluated using univariate and multivariate analyses, and compared with the last decade studies.

Result

The study population was 566 patients, 264 (46.64%), 224 (39.58%), and 78 (13.78%) patients with no, minor, and major LARS, respectively. In the univariate analysis, independent factors such as tumor location and size, anastomotic height, protective ileostomy, post-operation chemoradiotherapy, tumor T stage, lymphatic nodal metastasis classification, surgery duration, and time interval for closure of stoma were significantly associated with LARS points while we found the tumor T stage and lymphatic nodal metastasis classification as the new independent risk factors compared with the last decade studies. In the multivariate analysis, factors such as low and middle tumor location and protective ileostomy, and post operation treatment, nodal metastasis classification were the independent risk factors for major LARS.

Conclusion

The new independence risk factors were tumor T stage and lymphatic nodal metastasis status in univariate analysis in our study, with anastomotic height, low and middle tumor location, protective ileostomy, post-operation chemoradiotherapy, nodal metastasis status increasing LARS point in multivariate analysis after surgery for CRC.

1. Introduction

CRC is the third most common cancer in the world, accounting for more than a third of all cancer cases, with an age-standardized rate of 7.7 per 100,000[1–4]. With the advances in chemotherapy, radiotherapy, and surgical techniques, the long-term survival numbers are increasing after CRC surgery regardless of

the rising incidences of these diseases[5–7]. The major surgical procedure for CRC involves abdominoperineal resection (APR or called as Mile's procedure) and low anterior resection (LAR) with preservation of sphincter muscles. In recent years, LAR with total mesorectal excision (TME) is the gold standard in rectal cancer surgery[8, 9]. LAR and partial mesorectal resections are the most appropriate surgical procedures for upper rectal cancer[1, 5, 10, 11].

Laparoscopic LAR is a technically difficult procedure that involves transection of the intraperitoneal rectum in a limited pelvic cavity. several large randomized clinical trials have reported the safety and feasibility of this procedure[12, 13]. However, the undesirable result of this surgery is low anterior resection syndrome (LARS). The prevalence is around 80–90% and after sphincter-preserving CRC surgery, patients experienced LARS with varying degrees of severity[1–3, 9, 14, 15].

The conception of LARS is hard to define and involves some altered evacuation status after LAR. It can be described as a “disordered bowel function after rectal resection, leading to a detriment in quality of life.”[16–19]. LARS generally consists of fecal incontinence, urgency, and incomplete evacuation or evacuation difficulties. several articles reported the leakage of gas and stool, stool clustering, frequent bowel movements, evacuation, and urgency as the main complaints[1, 7, 16, 19–21]. LARS can have two types of symptoms, the first type appears within 6–12 months after surgery, which is called short-term symptoms. they are usually caused by short-lived neorectal irritabilities during the postoperative period. the second type extends for more than one year after surgery. they are called long-term symptoms and are most likely caused by constant changes[7]. Approximately 50% of patients experience symptoms of LARS after anal sphincter-preserving surgery with a follow-up of 11.1–14.6 years[1].

the etiology of LARS is poorly understood. the anatomical components and physiological functions of normal defecation, which may be damaged during surgery, are not well established[9, 22]. LAR surgery can injure components of the anal canal, such as the internal anal sphincter, longitudinal conjunctive muscle, or hiatus ligament, or can cause mechanical or nerve damage through injury to these organs. The resection of the rectum, division of the coccygeus muscle, and/or damage to the nerve supply can impair rectal function. the remaining rectum is small and does not function properly. the neorectum can functionally replace the resected rectum. It is usually constructed from the sigmoid and left colon. Hypermotility of the remnant colon can affect the manifestation of urge fecal incontinence. However, these kinds of coloplasty do not improve the quality of life (QoL) of LAR patients after CRC perfectly[7, 18, 19].

The colorectal experts thought that the best way to deal with this syndrome is to evaluate the LARS scoring and prevent it, and this idea for LARS scoring system first came up in 1998, and the Memorial Sloan Kettering Cancer Center Bowel Function Instrument (MSKCC-BFI) created the 18 items validated scoring system in 2004 that can be used to assess the bowel function after LAR[23]. This scoring system surveys several factors, including diet number, form, quality and timing of bowel movements, sensation of flatus, anti-diarrheal medication usage, and fecal incontinence. This scoring system ranged from 18 to 90, higher scores indicate better levels of bowel function. However, this scoring system was not

universally applicable and could not be widely used[1, 16, 24]. The second LARS scoring system is a five-item validated questionnaire created in 2012 for the Danish population that evaluates the bowel function after CRC surgery (Table 1)[5, 25, 26]. In recent years, this questionnaire has been used to evaluate LARS worldwide. Therefore, it is important to identify the risk factors of LARS using understandable scoring system and prevent this undesirable result of CRC surgery.

Table 1
LARS scoring system questionnaire

1. Do you ever have occasion when you cannot control your flatus (wind)?	
No, never	0
Yes, less than once per week	4
Yes, at least once per week	7
2. Do you ever have any accident leakage of liquid stool?	
No, never	0
Yes, less than once per week	3
Yes, at least once per week	3
3. How often do you open your bowels?	
More than 7 times per day (24h)	4
4–7 times a day (24h)	2
1–3 times a day (24h)	0
Less than once a day	5
4. Do you ever have to open your bowels again within 1h of the last bowel opening?	
No, never	0
Yes, less than once per week	9
Yes, at least once per week	11
5. Do you ever have such a strong urge to open your bowels that you have to rush to the toilet?	
No, never	0
Yes, less than once per week	11
Yes, at least once per week	16
0–20: No LARS	
21–29: Minor LARS	
30–42: Major LARS	

In this study, we tried to identify the independent risk factors influencing LARS after CRC resection and compared them with the last decade studies for the advanced research.

2. Materials And Method

2.1. Type of study

This was a cross-sectional study using prospectively collected information from the Second Affiliation Hospital of Dalian Medical University in China. All the patients were diagnosed with CRC and underwent sphincter-preserving LAR with intensive treatments from January 2017 to December 2019.

2.2. Population of study

Inclusion criteria

Any patient diagnosed with CRC was included in this study without any age or gender specifications, and tumor location ranging from 5–25 cm off the anal verge. All patients underwent colonoscopy, CT (or MRI test if necessary) and other tests, and were diagnosed as rectal cancer.

Exclusion criteria

1. Patients with unresectable cancers.
2. Patients assessed as more than ASA grade 3.
3. Patients with poor-quality total mesorectal excision (TME) surgery or breached circumferential tumor margins in complete mesocolic excision (CME) surgery.
4. Patients who underwent abdominal perineal resection (APR, also called as Miles procedure) or proctosigmoidectomy (Hartmann procedure).
5. Patients who did not complete the LARS questionnaire or follow-up.

Endpoints (outcome parameters)

Every patient was followed up for more than one year after LAR surgery and filled a LARS score questionnaire. the endpoint was the completion of the analysis in January 2021.

Operation

All resections were performed by five of professionally-certified and fellowship-trained colorectal surgeons, who all shared a similar case volume over the study years.

2.3. LARS Questionnaire and Data Collection

LARS questionnaire was used for assessing the bowel function and included the following items: flatus incontinence, liquid stools status, frequency, clustering, and urgency. Every item has three options with a defined scoring system used for evaluating the severity. The patients were divided into the no (0–20), minor (21–29), and major (30–42) LARS groups depending on their total score (Table 2).

Table 2
Distribution of patients according to LARS score and study variables (n = 566)

Variable	Level	LARS			p value
		No LARS	Minor LARS	Major LARS	
Gender	Male	178	136	40	0.066
	Female	86	88	38	
Age		64.50 ± 13	64.00 ± 14	64.00 ± 17	0.724
BMI		23.68 ± 2.89	23.82 ± 3.09	23.58 ± 3.63	0.776
Tumor location	Low	10	48	54	< 0.001*
	Middle	118	164	24	
	High	100	8	0	
	Sigmoid	36	4	0	
Tumor size		3.00 ± 3.00	4.00 ± 2.00	4.00 ± 2.1	0.028*
Anastomotic height		11.98 ± 4.40	7.31 ± 2.39	5.26 ± 1.27	< 0.001*
Operation type	Laparotomy	10	16	26	0.102
	Laparoscopy	254	208	52	
Protective ileostomy	Yes	174	54	6	< 0.001*
	No	90	170	72	
Pre-operation treatment	Yes	40	80	40	0.081
	No	224	144	38	
Post-operation treatment	Yes	168	116	36	0.020*
	No	96	108	42	
T stage	T1	16	14	2	0.009*
	T2	26	36	28	
	T3	100	80	22	
	T4	122	94	26	
Nodal classification	N0	170	136	48	0.059
	N1	74	66	22	
	N2	20	22	8	

Variable	Level	LARS			p value
		No LARS	Minor LARS	Major LARS	
Metastasis	M0	240	208	76	0.211
	M1	24	16	2	
Operation time		175.00 ± 65.99	187.50 ± 78.45	180.00 ± 93.83	0.005*
Time interval to close ileostomy		41.61 ± 75.96	102.16 ± 89.82	135.56 ± 106.71	< 0.001*
*: significant differences between the LARS subgroups					

We used the Chinese version of the questionnaire. Patient demographics, pre-and-post operative data, surgery information, and pathological data were obtained from the hospital database, and the three groups were compared. We measured the tumor location using the specimen from the anal verge after surgery, and the tumor location was divided into four degrees, such as low (= < 5 cm), middle (5–10 cm), high (10–15 cm), and sigmoid (> 15 cm). The anastomotic height was measured based on the tumor location and operation procedure in the surgery. The cancer stage was defined using the 8th edition American Joint Commission on Cancer (AJCC) Tumor Node Metastasis (TMN) classification system. In this study, the pathological stage was defined as the cancer stage after surgery.

2.4. Follow up

LARS scores were assessed for more than one year after an operation during follow-up. In this study, patients received phone calls and explained the questionnaire in detail, and they were asked to complete a validated Chinese version of the questionnaire designed to evaluate LARS score after CRC surgery. We rechecked the addresses and phone numbers for the patients who did not receive the calls, then reminded them or their family members to complete the questionnaire. The follow-up process was completed over three months.

2.5. Last decade studies database

We searched the PubMed (“Title/Abstract” add to the query box) and Web of Science Core Collection database (“TI = Title” and “AB = Abstract” add to the query box) from January 2011 to December 2021, using a combination of relevant Medical Subject Heading terms and keywords: (low anterior resection* OR LAR* OR low anterior resection syndrome* OR LARS*) AND (risk factor* OR independent factor* OR independent risk factor* OR quality of life* OR QoL*) AND (rectal cancer* OR colorectal cancer* OR colon cancer*) AND (surgery* OR operation* OR resection*). And we selected the most cited and suitable 21 papers, which researched about the risk factors of LARS among the 3450 papers (642 papers from PubMed, 2808 papers from Web of Science), and summarized their risk factors (Table 5).

Table 5
The independence risk factors of LARS

Author	Country	Published Year	Independence Risk Factors of LARS	Outcomes (OR, 95%CI value/ <i>p</i> value/RR value)
Bregendahl[50]	Denmark	2013	Neoadjuvant therapy	2.48 (1.73–3.55)
			TME procedure	2.31 (1.69–3.16)
			Age < 64 years old	1.9 (1.43–2.51)
			Female gender	1.93 (1.43–2.51)
			Anastomotic leakage	1.35 (1.02–1.79)
				2.06 (0.93–4.55)
Juul[51]	multicenter international Denmark, Spain, Sweden, Germany	2014	Radiotherapy	< 0.0001
			Mean tumor distance from anal verge	= 0.003
Juul[52]	Denmark + UK	2015	Neoadjuvant chemoradiation	3.5 (1.15–9.4)
			Anastomosis height	= 0.0001
Bondeven[53]	Denmark	2015	Long course neoadjuvant chemotherapy	3.5 (1.15–9.4)
			Remnant rectum < 4cm	= 0.0001
Cameron I. Wells[54]	New Zealand	2015	Low anastomosis height	2.11 (1.05–4.27); <i>p</i> = 0.04
			Obstructive presenting symptoms	6.71 (1.00–44.80); <i>p</i> = 0.05
			Post-operative chemotherapy (at 1 year)	1.93 (1.04–3.57); <i>p</i> = 0.03
			Temporary diverting ileostomy	2.49 (1.04–5.95); <i>p</i> = 0.04

Author	Country	Published Year	Independence Risk Factors of LARS	Outcomes (OR, 95%CI value/p value/RR value)
Hain[55]	France	2016	Long course radiotherapy	= 0.0007
			Anastomotic leakage	= 0.02
			Hand-sewn anastomosis	= 0.003
			Side-to-end anastomosis	= 0.01
Carillo[56]	Spain	2016	Long course radiotherapy	= 0.019
			TME (total mesorectal excision) / PME (partial mesorectal excision)	< 0.001
			Protective ileostomy Yes / No	= 0.003
			Coloplasty Yes (lower rate of LARS) / No (high rate of LARS)	0.017
Ekkarat[34]	Thailand	2016	Adjuvant radiotherapy (neoadjuvant excluded)	6.55 (2.37–18.15)
			Anastomosis height < 5cm	3.76 (1.34–10.61)
			Protective ileostomy	= 0.024
Sturiale[57]	Italy	2016	Neoadjuvant radiotherapy	= 0.04
			Tumor location from anal verge < 5cm	= 0.003
			Age > 70 years old	= 0.003
			Time interval for closure of ileostomy	= 0.002
Hughes[58]	Wales	2017	Neoadjuvant radiation	< 0.01
			Tumor location < 8cm	1.6 (0.6–4.1)
			Ileostomy close interval > 1year	3.7 (1.1–13.1)

Author	Country	Published Year	Independence Risk Factors of LARS	Outcomes (OR, 95%CI value/p value/RR value)
Emmertsen[59]	Denmark	2018	Radiotherapy Tumor height < 5cm	< 0.001 < 0.001
T. Sarcher[60]	France	2018	Neo-adjuvant treatment TME versus PME Anastomotic leak Female gender Age < 64 years old	RR = 2.48 RR = 2.31 RR = 2.06 RR = 1.35 RR = 1.90
Michał M. Nowakowski[61]	Poland	2018	Preoperative radiotherapy Distance of the tumor from the anal verge Bowel preparation Protective ileostomy	11.9 (2.98–47.48); p < 0.001 0.69 (0.55–0.86); p = 0.001 6.27 (1.51–26.7); p = 0.01 15.97 (4.07–61.92); p = 0.001
Weipeng Sun[62]	China	2018	Long-course neoadjuvant radiation Height of anastomosis Diverting ileostomy	2.20 (1.24–3.91); p = 0.007 0.74 (0.63–0.88); p = 0.001 2.59 (1.27–5.30); p = 0.009
Frederiek Nuytens[63]	Belgium	2018	Postoperative radiotherapy	< 0.04
Mateusz Rubinkiewicz[64]	Poland	2019	Post-operation complication	= 0.02

Author	Country	Published Year	Independence Risk Factors of LARS	Outcomes (OR, 95%CI value/ <i>p</i> value/RR value)
Fernanda Letícia Cavalcante Miacc[65]	UK	2019	Distance from the anastomosis to the anal margin	< 0.001
			Neoadjuvant therapy	< 0.0014
			Protective ileostomy	0.0023
W. S. Bolton[66]	UK	2020	Every 1 cm decrease in tumor height above the anal verge	1.290 (1.101,1.511)
			ASA grade > 1	2.920 (1.239, 6.883)
A. Dulskas[67]	Lithuania	2020	Preoperative chemoradiotherapy	< 0.001
G. Rizzo[68]	Italy	2021	Preoperative chemoradiotherapy	< 0.012
Sami BENLİ[69]	Turkey	2021	Very low anterior resection procedure	42.40 (11.14-161.36); <i>p</i> < 0.0001
			Protective ileostomy	12.83 (6.58-25.0); <i>p</i> < 0.0001
			End colostomy	8.55 (1.36-53.61); <i>p</i> = 0.022
			Chemotherapy	3.08 (1.71-5.53); <i>p</i> < 0.0001
			Radiotherapy	2.51 (1.38-4.57); <i>p</i> = 0.003
			Anastomosis location > 8.5cm	< 0.05

=/ <***; *p* value, ** (**-**); OR (95% CI) value, RR; relative risk value

2.6. IRB approval/Ethics

The Ethics Committee of the Second Affiliation Hospital of Dalian Medical University approved this study. All patients were given information regarding the surgery and informed consent was obtained before surgery.

2.7. Statistical Analysis

All data collection and statistical analyses were performed using EndNote 20.0, Excel 2019, and Social Science SPSS Advanced Statistics 26.0 (IBM Software Group). The mean, standard deviation, and median values (interquartile range) were used to describe the normal and non-normal distribution measurement data. frequency (percentage) was used to describe the classification data. The one-way ANOVA and nonparametric tests were used to compare the measurement and classification data between the groups. Statistical significance was set at $p < 0.05$.

First, we used univariate analysis to find factors with significant associations with LARS. then, we performed the multivariate analysis with the variables representing significant differences in the univariate analysis. We confirmed the risk factors associated with LARS using the ordered logistic regression analysis.

3. Result

We collected 660 patient data from the hospital database, and 566 patients responded completely (85.76%). Among the 660 patients, 32 could not be contacted, 26 did not respond, 29 returned incomplete questionnaires, and seven died because of several causes, including the other diseases or accidents. We excluded these 94 patients from the analyses. Therefore, the study population was 566 patients with 354 men and 221 women (Fig. 1).

the mean age was 63.44 y (64.60 y and 61.50 y for men and women, respectively). The median follow-up was 15.6 months (10–22 months) after surgery. Depending on the LARS score, we divided the patients into the no LARS, minor LARS, and major LARS groups with 264 (46.64%), 224 (39.58%), and 78 (13.78%) patients, respectively. laparoscopic surgery and protective ileostomy were performed on 514 (90.81%) and 354 (41.34%) patients, respectively. there were 10 incidences of anastomosis leakage (1.8%) (Table 2).

The results of the univariate analysis are shown in Table 3. LARS was significantly more frequent in patients with factors, such as low tumor location (Low: OR = 1.589, 95% CI = 1.272–2.278, Middle: OR = 1.293, 95% CI = 1.009–1.577, High: OR = 1.026, 95% CI = 1.011–1.259) and tumor size (OR = 0.069, 95% CI = 0.032–0.363), anastomotic height (OR = 0.67, 95% CI = 0.59–0.75), protective ileostomy versus no ileostomy (OR = 1.664, 95% CI = 1.513–1.863), post-operation chemoradiotherapy (OR = 0.139, 95% CI = 0.028–0.358), tumor T stage (T1: OR = 1.041, 95% CI = 0.332–1.403, T2: OR = 0.419, 95% CI = 0.181–0.657, T3: OR = 0.991, 95% CI = 0.194–1.173), nodal classification (N0: OR = 1.105, 95% CI = 0.193–1.402, N1: OR = 1.081, 95% CI = 0.238–1.400), long surgery duration (OR = 1.476, 95% CI = 1.336–2.336), and time interval between ileostomy closure (OR = 3.131, 95% CI = 0.742–3.258). In contrast, gender, age, BMI, surgery type (laparoscopy or open procedure), pre-operation chemoradiotherapy, and tumor metastases were not associated with LARS development (Table 3). We compared these factors with the last decade

studies mentioned about the risk factors of LARS (Table 5), and we clarified the tumor T stage and lymphatic nodal metastasis classification were the new factors in our study.

Table 3
Result of univariate analysis

Variable	Level	Odds ratio (95% confidence interval)	p value
Gender	Male	1.163 (0.066–1.333)	0.519
	Female	1	
Age		0.97 (0.94–1.0)	0.628
BMI		1.589 (1.272–2.278)	0.120
Tumor location	Low	1.293 (1.009–1.577)	< 0.0001*
	Middle	0.593 (0.334–0.852)	
	High	1.026 (1.011–1.259)	
	Sigmoid	1	
Tumor size		0.069 (0.032–0.363)	< 0.0001*
Anastomotic height		0.67 (0.59–0.75)	< 0.0001*
Operation Type	Laparotomy	1.333 (1.052–2.719)	0.471
	Laparoscopy	1	
Protective ileostomy	Yes	1.664 (1.513–1.863)	< 0.0001*
	No	1	
Pre-operation Treatment	Yes	1.338 (1.836–2.519)	0.182
	No	1	
Post-operation Treatment	Yes	0.139 (0.028–0.358)	0.022*
	No	1	
T stage	T1	1.041 (0.322–1.403)	0.001*
	T2	0.419 (0.181–0.657)	
	T3	0.911 (0.194–1.173)	
	T4	1	
Nodal classification	N0	1.105 (0.193–1.402)	0.014*
	N1	1.081 (0.238-1.400)	
	N2	1	
Metastasis	M0	0.81 (0.525–1.104)	0.188

Variable	Level	Odds ratio (95% confidence interval)	<i>p</i> value
	M1	1	
Operation time		1.476 (1.336–2.336)	0.038*
Time interval to close ileostomy		3.131 (0.742–3.258)	0.002*
*: significant differences			

In the multivariate analysis, the independent risk factors related with LARS were anastomotic height (OR = 1.028, 95% CI = 0.428–1.714), low (OR = 80.39, 95% CI = 15.21-424.54) and middle tumor locations (OR = 11.03, 95% CI = 2.33–56.25), nodal classification (N0: OR = 0.715, 95% CI = 0.193–1.102, N1: OR = 0.981, 95% CI = 0.238–1.336) and protective ileostomy (OR = 0.35, 95% CI = 0.16–0.79) (Table 4).

Table 4
Result of multivariate analysis

Multivariate and levels		Odd ratio (95% CI)	p value
Tumor size (diameter)		1.02 (0.86– 1.20)	0.813
Operation time		1.00 (0.997– 1.004)	0.705
Time intervals to close stoma		1.003 (0.999– 1.006)	0.132
Anastomotic height		8.028 (4.428– 21.714)	< 0.001*
Tumor location	Low	80.39 (15.21- 424.54)	< 0.001*
	Middle	11.03 (2.33– 56.25)	0.002*
	High	0.86 (0.13– 5.46)	0.871
	Sigmoid	1	
Protective Stoma (ileostomy)	Yes	0.35 (0.16– 0.79)	0.01*
	No	1	
Postoperation Treatment	Yes	1.39 (0.79– 2.40)	0.047*
	No	1	
T stage	T1	0.87 (0.25– 3.02)	0.824
	T2	1.84 (0.85– 3.98)	0.121
	T3	0.85 (0.46– 1.56)	0.594
	T4	1	
Nodal classification	N0	0.715 (0.193– 1.102)	0.022*

Multivariate and levels		Odd ratio (95% CI)	<i>p</i> value
	N1	0.981 (0.238– 1.336)	0.038*
	N2	1	
*: significant differences			

4. Discussion

sphincter-preserving low anterior resection (LAR) improves the quality of life (QoL) of patients with middle and low colorectal cancer; Therefore, it has become a popular treatment method[27, 28]. However, the undesirable result of this procedure is the bowel dysfunction called low anterior resection syndrome[29]. About 80% of patients who undergo this procedure experience varying degrees of LARS[30, 31].

There are two types of LARS. The first includes fecal urgency, incontinence, and increased frequency. The second includes constipation, feelings of incomplete excretion, and bowel-emptying difficulties[10, 20]. Some patients show characteristics of both types. They alternate between the two patterns or experience both at the same time[32–35]. these symptoms are caused because of damage to several factors, such as nerves and muscles of defecation[22, 28, 36].

The risk factors of severe LARS are related to the anastomotic height, pre and postoperative chemoradiotherapy, anastomotic leakage, and protective ileostomy etc.[8, 9, 34, 37, 38].

In our study, we firstly identified the independent risk factors associated with LARS in univariate analysis, including tumor location and tumor size, anastomotic height, protective ileostomy versus no ileostomy, post-operation chemoradiotherapy, tumor T stage, nodal classification, long surgery duration, and time interval between ileostomy closure, while the tumor T stage and nodal classification were clarified as the new independent risk factors compared with the last decade studies.

When having low anterior resection procedure for CRCs, it takes time for the bowel to adapt after the operation, which helps in intestinal function recovery. And protective ileostomy was performed, the patients have difficulties controlling their defecation. The loss of bowel functions leads to stool defecation without consciousness, and this phenomenon adversely affects LARS recovery.

tumor location, size, T stage and lymphatic nodal characteristics are directly related to surgical range and procedures; therefore, LARS is directly influenced by these three factors[39–41]. But this theory is suggested in our study and the other studies have no mentioned the tumor T stage and nodal classification as the risk factors in their researches.

the side effect of neoadjuvant radiotherapy and chemotherapy is intestinal dysfunction, which is caused by nerve and muscle damage in the colon[38, 42–44]. In 2017, L.M.Jimenez-Gomez et al.,[8] reported risk factors, such as TME and neoadjuvant and adjuvant radiotherapy can increase the risk of major LARS. In 2020, Theresa H. Nguyen et al.,[1] proved that neoadjuvant and adjuvant radiotherapy were risk factors for LARS, especially major LARS, even in patients with large rectal residuals. And several studies have shown that LARS is divided into incontinence-dominant and frequency-dominant modes. Each mode is associated with different risk factors. The incontinence-dominant mode is related to preoperative radiotherapy and postoperative complications. the frequency-dominant mode is related to the low tumor location from the anal margin; however, the overall main LARS is related to poor quality of life. The frequency-dominant type of LARS has a more profound impact on postoperative quality of life[10, 26, 45]. In 2019, Keiji Koda et al.,[22] showed that removing most of the rectum can damage the internal sphincter muscle and/or rectal wall, and deconstruct structures around the levator hiatus, are factors involved in the development of LARS symptoms.

In recent years, significant incidences of postoperative intestinal dysfunction and the prospects of a good prognosis have made radical resection plus neoadjuvant radiotherapy the standard treatment. However, there are some practical difficulties to perform the complete radical resection. In this theory, full-dose neoadjuvant chemotherapy can reduce tumor size similar to radiotherapy plus chemotherapy, reducing the possibilities of local recurrence in patients undergoing surgical resection. It also reduces the incidences of distant metastases. These studies have shown that neoadjuvant chemotherapy is usually an effective method for the treatment of locally advanced rectal cancer, and the effects are satisfactory[46, 47]. Considering that neoadjuvant chemotherapy has no significant effect on bowel function, it may be a reasonable treatment option for major LARS patients[48].

In our study, only post-operative chemoradiotherapy was identified as a risk factor for severe LARS development in terms of neoadjuvant and adjuvant treatment of CRCs. We thought that this result came from the differences in treatments and conditions according to every country and national race.

In 2021, Suzuki, N et al.,[49] also reported anastomotic complications, such as leakage, which was confirmed to be associated with a 3.5-fold increase in the incidences of major LARS. However, we could not find anastomotic complications increasing the incidences of major LARS in our study, and we thought this was due to the development of operation skills and reliable management of patients after operation in recent years.

several studies have suggested an algorithm for the treatment of LARS, including conservative therapies, biofeedback, and sacral nerve stimulation. In 2019, Chirs George et al.,[42] reported that conservative treatment (internal medicine, physical therapy, and trans-anal irrigation), invasive surgery (neuromodulation), and multimodal therapy were the main methods for treating LARS in patients. If these treatments were not working wonderfully, it's recommended to perform stoma surgery. the definitive stoma surgery was considered if major LARS persisted for more than 2 years [7, 21, 28]. In 2021, K. Neumann et.al.,[50] found that transanal endoscopic microsurgery (TEM) for rectal tumors was

associated with significantly reduced hospitalization costs, which far exceeded the cost of acquiring and maintaining the technology, and reduced the incidence of LARS, so recommended that if possible use TEM to treat rectal cancer.

When we are focusing on the number of articles published each year for the last ten years, the publications and citations trend to increase obviously (Fig. 2: downloaded from Web of Science Core Collection). this shows that research for LARS and improving QoL is recently one of the major focuses in the colorectal fields as patient requests. And, the independent factors are similar to the others, including pre- and post-surgery chemoradiotherapy, poor TME procedure, tumor height from the anal verge, anastomosis height and leakage, temporary protective ileostomy, and complications after surgery (Table 5). we thought it would give a well-updated knowledge for future studies. We thought there are some limitations in our study such as not enough numbers of database, single institution study design and no mentions on LARS treatment. these can affect the undesirable effects on the study results and general ideas. We hope an updated and advanced study is needed for a better understanding to provide more information on LARS treatment strategies improving the quality of life.

5. Conclusion

The new independence risk factors were tumor T stage and lymphatic nodal metastasis status in univariate analysis, while anastomotic height, low and middle tumor location, protective ileostomy, post-operation chemoradiotherapy, nodal metastasis status were increasing LARS points after CRC surgery in multivariate analysis in our study.

Declarations

Author Contributions

Conceptualization, HyokJu Ri, Xin Chen and ZhaoHui Xu; investigation, ZhaoHui Xu, Hui Qu, ZeZhong Gong; data curation, GunHyok Kim, YanYing Ren, BOUREIMA.H AMADOU; writing-original draft preparation; HyokJu Ri, ZhaoHui Xu; writing-review and editing; HyokJu Ri, Xin Chen, YanYing Ren; supervision and project administration, HyokJu Ri, ZhaoHui Xu, Xin Chen. All authors have read and agreed to the published version of the manuscript.

Conflict of interest

The authors declared no conflict of interest with respect to the authorship and/or publication of this article.

Acknowledgments

The authors are thankful to the Second Affiliation Hospital of Dalian Medical University for the sufficient database.

Funding

This research received no external funding.

References

1. Nguyen, T.H. and R.V. Chokshi, *Low Anterior Resection Syndrome*. Curr Gastroenterol Rep, 2020. **22**(10): p. 48.
2. Vollebregt, P.F., et al., *Altered anal slow-wave pressure activity in low anterior resection syndrome: short case series in two independent specialist centres provide new mechanistic insights*. Colorectal Dis, 2021. **23**(2): p. 444-450.
3. McDermott, F.D., *Altered colonic motility is associated with low anterior resection syndrome, by Keane et al*. Colorectal Dis, 2021. **23**(2): p. 338.
4. Pieniowski, E.H.A., et al., *Prevalence of low anterior resection syndrome and impact on quality of life after rectal cancer surgery: population-based study*. BJS Open, 2020. **4**(5): p. 935-942.
5. Buchli, C., A. Martling, and A. Sjovall, *Low anterior resection syndrome after right- and left-sided resections for colonic cancer*. BJS Open, 2019. **3**(3): p. 387-394.
6. Stelzner, S., J. Kupsch, and S.T. Mees, *[Low anterior resection syndrome-Causes and treatment approaches]*. Chirurg, 2021.
7. Christensen, P., et al., *Management guidelines for low anterior resection syndrome - the MANUEL project*. Colorectal Dis, 2021. **23**(2): p. 461-475.
8. Jimenez-Gomez, L.M., et al., *Factors associated with low anterior resection syndrome after surgical treatment of rectal cancer*. Colorectal Dis, 2017.
9. Sapci, I., et al., *Factors associated with noncomplete mesorectal excision following surgery for rectal adenocarcinoma*. Am J Surg, 2019. **217**(3): p. 465-468.
10. Kim, M.J., et al., *Two dominant patterns of low anterior resection syndrome and their effects on patients' quality of life*. Sci Rep, 2021. **11**(1): p. 3538.
11. Zhou, X., et al., *Risk Factors Associated With Nonclosure of Defunctioning Stomas After Sphincter-Preserving Low Anterior Resection of Rectal Cancer: A Meta-Analysis*. Dis Colon Rectum, 2017. **60**(5): p. 544-554.
12. Farag, A., A.N. Mashhour, and M.Y. Elbarmelgi, *Taeniectomy Versus Transverse Coloplasty as Neorectum After Low Rectal Resection*. World J Surg, 2019. **43**(4): p. 1137-1145.
13. Shimizu, H., et al., *Who needs diverting ileostomy following laparoscopic low anterior resection in rectal cancer patients? Analysis of 417 patients in a single institute*. Surg Endosc, 2020. **34**(2): p. 839-846.
14. Keane, C., et al., *Altered colonic motility is associated with low anterior resection syndrome*. Colorectal Dis, 2021. **23**(2): p. 415-423.

15. Rodrigues, B., et al., *Feasibility Study of Transanal Irrigation Using a Colostomy Irrigation System in Patients with Low Anterior Resection Syndrome*. Dis Colon Rectum, 2021.
16. Hu, J., et al., *Knowledge, attitudes, practices, and related factors of low anterior resection syndrome management among colorectal surgery nurses: a multicenter cross-sectional study*. Support Care Cancer, 2021.
17. Pape, E., et al., *Impact of low anterior resection syndrome (LARS) on the quality of life and treatment options of LARS - A cross sectional study*. Eur J Oncol Nurs, 2021. **50**: p. 101878.
18. Moon, J., et al., *Interactive online informational and peer support application for patients with low anterior resection syndrome: patient survey and protocol for a multicentre randomized controlled trial*. Colorectal Dis, 2021. **23**(5): p. 1248-1257.
19. Keane, C., et al., *International consensus definition of low anterior resection syndrome*. Colorectal Dis, 2020. **22**(3): p. 331-341.
20. Martellucci, J., *Low Anterior Resection Syndrome: A Treatment Algorithm*. Dis Colon Rectum, 2016. **59**(1): p. 79-82.
21. Rasulov, A.O., et al., *[Surgical treatment of low anterior resection syndrome]*. Khirurgiia (Mosk), 2020(11): p. 53-60.
22. Koda, K., et al., *Etiology and management of low anterior resection syndrome based on the normal defecation mechanism*. Surg Today, 2019. **49**(10): p. 803-808.
23. Essangri, H., et al., *Transcultural adaptation and validation of the Moroccan Arabic dialect version of the Wexner incontinence score in patients with low anterior resection syndrome after rectal surgery*. Surgery, 2021.
24. Burke, J.P., *Low anterior resection syndrome - 'braking' our focus with the pelvis*. Colorectal Dis, 2021. **23**(2): p. 339-340.
25. Dalsgaard, P., et al., *Nurse-led standardized intervention for low anterior resection syndrome. A population-based pilot study*. Colorectal Dis, 2021. **23**(2): p. 434-443.
26. Mekhael, M., et al., *Transanal Irrigation for Neurogenic Bowel Disease, Low Anterior Resection Syndrome, Faecal Incontinence and Chronic Constipation: A Systematic Review*. J Clin Med, 2021. **10**(4).
27. Sakr, A., et al., *Assessment and management of low anterior resection syndrome after sphincter preserving surgery for rectal cancer*. Chin Med J (Engl), 2020. **133**(15): p. 1824-1833.
28. Keane, C., et al., *Defining low anterior resection syndrome: a systematic review of the literature*. Colorectal Dis, 2017. **19**(8): p. 713-722.
29. van der Heijden, J.A.G., et al., *Transanal total mesorectal excision and low anterior resection syndrome*. Br J Surg, 2021.
30. Marti, W.R., et al., *Clinical Outcome After Rectal Replacement With Side-to-End, Colon-J-Pouch, or Straight Colorectal Anastomosis Following Total Mesorectal Excision: A Swiss Prospective, Randomized, Multicenter Trial (SAKK 40/04)*. Ann Surg, 2019. **269**(5): p. 827-835.

31. Bazzell, A., L.T. Madsen, and J. Dains, *Clinical Management of Bowel Dysfunction After Low Anterior Resection for Rectal Cancer*. J Adv Pract Oncol, 2016. **7**(6): p. 618-629.
32. Dulskas, A., et al., *Treatment possibilities for low anterior resection syndrome: a review of the literature*. Int J Colorectal Dis, 2018. **33**(3): p. 251-260.
33. Farella, M., et al., *Surgical Management by Disk Excision or Rectal Resection of Low Rectal Endometriosis and Risk of Low Anterior Resection Syndrome: A Retrospective Comparative Study*. J Minim Invasive Gynecol, 2021.
34. Nocera, F., et al., *Optimising functional outcomes in rectal cancer surgery*. Langenbecks Arch Surg, 2021. **406**(2): p. 233-250.
35. Keane, C., et al., *Functional outcomes from a randomized trial of early closure of temporary ileostomy after rectal excision for cancer*. Br J Surg, 2019. **106**(5): p. 645-652.
36. Theodoropoulos, G.E., et al., *Temporal Changes of Low Anterior Resection Syndrome Score after Sphincter Preservation: A Prospective Cohort Study on Repetitive Assessment of Rectal Cancer Patients*. J Invest Surg, 2021: p. 1-9.
37. Ekkarat, P., et al., *Factors determining low anterior resection syndrome after rectal cancer resection: A study in Thai patients*. Asian J Surg, 2016. **39**(4): p. 225-31.
38. Zhang, Q., et al., *The impact of neoadjuvant chemotherapy on low anterior resection syndrome after rectal cancer resection: A 6 Months longitudinal follow-up*. Asian J Surg, 2021.
39. Greenwood, A., et al., *Brief report: Lymph node morphology in stage II colorectal cancer*. PLoS One, 2021. **16**(3): p. e0249197.
40. Naxerova, K., et al., *Origins of lymphatic and distant metastases in human colorectal cancer*. Science, 2017. **357**(6346): p. 55-60.
41. Jin, M. and W.L. Frankel, *Lymph Node Metastasis in Colorectal Cancer*. Surg Oncol Clin N Am, 2018. **27**(2): p. 401-412.
42. Cura Pales, C.G., et al., *Postoperative Bowel Function After Anal Sphincter-Preserving Rectal Cancer Surgery: Risks Factors, Diagnostic Modalities, and Management*. Ann Coloproctol, 2019. **35**(4): p. 160-166.
43. Ziv, Y., et al., *Low anterior resection syndrome (LARS): cause and effect and reconstructive considerations*. Tech Coloproctol, 2013. **17**(2): p. 151-62.
44. Chen, T.Y., et al., *Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial*. Clin Colorectal Cancer, 2015. **14**(2): p. 106-14.
45. Keramati, M.R., et al., *Translation, validation and psychometric evaluation of the Persian (Farsi) version of the Low Anterior Resection Syndrome Score (LARS-P)*. PLoS One, 2021. **16**(2): p. e0247054.
46. Kaneko, M., et al., *Neoadjuvant Imatinib Therapy Followed by Intersphincteric Resection for Low Rectal Gastrointestinal Stromal Tumors*. Anticancer Res, 2017. **37**(9): p. 5155-5160.

47. Kosugi, C., et al., *Evaluation of Preoperative Chemotherapy with Modified OPTIMOX-1 Plus Bevacizumab in Patients with Advanced Rectal Cancer with Factors Contraindicative of Curative Surgery*. *Hepatogastroenterology*, 2015. **62**(140): p. 868-72.
48. Zhang, Q., et al., *The impact of neoadjuvant chemotherapy on low anterior resection syndrome after rectal cancer resection: A 6 Months longitudinal follow-up*. *Asian J Surg*, 2021.
49. Suzuki, N., et al., *Determining the protective characteristics and risk factors for the development of anastomotic leakage after low anterior resection for rectal cancer*. *Surg Today*, 2021. **51**(5): p. 713-720.
50. Neumann, K., et al., *Cost Analysis of Laparoscopic Low Anterior Resection vs. Transanal Endoscopic Microsurgery for Rectal Neoplasms*. *Curr Oncol*, 2021. **28**(3): p. 1795-1802.

Figures




Figure 1

Patients collection diagram. This was a cross-sectional, single institution study with colorectal cancer who had undergone low anterior resection from January 2017 to December 2019.




Figure 2

Paper publication and citation numbers in the last ten years (2011-2021)